Morgan Stanley Upgrades C4 Therapeutics to Equal-Weight, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has upgraded C4 Therapeutics from Underweight to Equal-Weight, but lowered the price target from $3 to $1.

November 06, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
C4 Therapeutics' rating has been upgraded by Morgan Stanley, but the price target has been lowered.
The upgrade from Underweight to Equal-Weight suggests that Morgan Stanley sees potential in C4 Therapeutics. However, the lowering of the price target from $3 to $1 indicates a potential decrease in the stock's value. This mixed signal could lead to uncertainty in the market, potentially keeping the stock's price stable in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100